GWS
AMLX icon

Glassman Wealth Services’s Amylyx Pharmaceuticals AMLX Stock Holding History

Glassman Wealth Services’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39
Closed -$1K – 1638
2022
Q2 		$1K Buy
+39
New +$463 ﹤0.01% 1334

Other funds holding AMLX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Glassman Wealth Services's AMLX Position: Q3 2022 in Review

Glassman Wealth Services sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2022, closing a stake of 39 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in AMLX in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 95 funds tracked by Wall St. Rank hold AMLX as of Q3 2022.

  • Glassman Wealth Services reported no remaining Amylyx Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 39 Amylyx Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • Glassman Wealth Services first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Glassman Wealth Services's Amylyx Pharmaceuticals position peaked at $1K in Q2 2022.
  • 95 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2022.

Based on Glassman Wealth Services's 13F filing for Q3 2022, filed 9 Nov 2022.